Ancillary techniques play an essential role in pulmonary cytopathology. Immunoperoxidase and special stains are by far the most common ancillary techniques used in cytopathology; however, the role of molecular diagnosis is growing, especially in the fields of pulmonary oncology and infectious disease. In this article, we review the uses of ancillary techniques in lung tumor diagnosis, lung tumor classification, predictive marker determination, primary versus metastasis differential diagnosis, and infectious organism detection.

1.
Siegel
RL
,
Miller
KD
,
Jemal
A
.
Cancer statistics, 2018
.
CA Cancer J Clin
.
2018
Jan
;
68
(
1
):
7
30
.
[PubMed]
0007-9235
2.
National Comprehensive Cancer Network
. NCCN guidelines version 2.
2019
non-small cell lung cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Last updated 21 November 2018 [Accessed 13 December 2018] https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
3.
Yatabe
Y
,
Dacic
S
,
Borczuk
AC
,
Warth
A
,
Russell
PA
,
Lantuejoul
S
, et al
Best practices recommendations for diagnostic immunohistochemistry in lung cancer
.
J Thorac Oncol
.
2019
Mar
;
14
(
3
):
377
407
.
[PubMed]
1556-0864
4.
Aisner
DL
,
Rumery
MD
,
Merrick
DT
,
Kondo
KL
,
Nijmeh
H
,
Linderman
DJ
, et al
Do more with less: tips and techniques for maximizing small biopsy and cytology specimens for molecular and ancillary testing: the University of Colorado experience
.
Arch Pathol Lab Med
.
2016
Sep
;
140
(
11
):
1206
20
.
[PubMed]
0003-9985
5.
Tian
SK
,
Killian
JK
,
Rekhtman
N
,
Benayed
R
,
Middha
S
,
Ladanyi
M
, et al
Optimizing workflows and processing of cytologic samples for comprehensive analysis by next-generation sequencing: Memorial Sloan Kettering Cancer Center experience
.
Arch Pathol Lab Med
.
2016
Sep
;
140
(
11
):
1200
5
.
[PubMed]
0003-9985
6.
Roy-Chowdhuri
S
,
Aisner
DL
,
Allen
TC
,
Beasley
MB
,
Borczuk
A
,
Cagle
PT
, et al
Biomarker tsting in lung carcinoma cytology specimens: a perspective from members of the Pulmonary Pathology Society
.
Arch Pathol Lab Med
.
2016
;
140
(
11
):
1267
72
. 0003-9985
7.
Moreira
AL
. Role of immunohistochemistry in the detection of targetable mutations. In:
Moreira
AL
,
Saqi
A
, editors
.
Diagnosing non-small cell carcinoma in small biopsy and cytology
.
New York
:
Springer
;
2015
. pp.
109
27
.
8.
Layfield
LJ
,
Pearson
L
,
Walker
BS
,
White
SK
,
Schmidt
RL
.
Diagnostic accuracy of fine-needle aspiration cytology for discrimination of squamous cell carcinoma from adenocarcinoma in non-small cell lung cancer: a systematic review and meta-analysis
.
Acta Cytol
.
2018
;
62
(
5-6
):
318
26
.
[PubMed]
0001-5547
9.
Travis
WD
,
Brambilla
E
,
Noguchi
M
,
Nicholson
AG
,
Geisinger
KR
,
Yatabe
Y
, et al
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma
.
J Thorac Oncol
.
2011
Feb
;
6
(
2
):
244
85
.
[PubMed]
1556-0864
10.
Travis
WD
,
Brambilla
E
,
Burke
AP
,
Marx
A
,
Nicholson
AG
, editors
.
WHO classification of tumours of the lung, pleura, thymus and heart
, ed 4. Lyon, France, International Agency for Research on Cancer (IARC),
2015
, vol 7.
11.
Lozano
MD
,
Echeveste
JI
,
Abengozar
M
,
Mejías
LD
,
Idoate
MA
,
Calvo
A
, et al
Cytology smears in the era of molecular biomarkers in non-small cell lung cancer: doing more with less
.
Arch Pathol Lab Med
.
2018
Mar
;
142
(
3
):
291
8
.
[PubMed]
0003-9985
12.
Kawahara
A
,
Fukumitsu
C
,
Azuma
K
,
Taira
T
,
Abe
H
,
Takase
Y
, et al
A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients
.
Cytopathology
.
2018
Apr
;
29
(
2
):
150
5
.
[PubMed]
0956-5507
13.
Kawahara
A
,
Fukumitsu
C
,
Taira
T
,
Abe
H
,
Takase
Y
,
Murata
K
, et al
Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings
.
Cancer Cytopathol
.
2015
Oct
;
123
(
10
):
620
8
.
[PubMed]
1934-662X
14.
Thunnissen
E
,
Allen
TC
,
Adam
J
,
Aisner
DL
,
Beasley
MB
,
Borczuk
AC
, et al
Immunohistochemistry of pulmonary biomarkers: a perspective from members of the Pulmonary Pathology Society
.
Arch Pathol Lab Med
.
2018
Mar
;
142
(
3
):
408
19
.
[PubMed]
0003-9985
15.
Moreira
AL
,
Hasanovic
A
.
Molecular characterization by immunocytochemistry of lung adenocarcinoma on cytology specimens
.
Acta Cytol
.
2012
;
56
(
6
):
603
10
.
[PubMed]
0001-5547
16.
Hasanovic
A
,
Ang
D
,
Moreira
AL
,
Zakowski
MF
.
Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma
.
Lung Cancer
.
2012
Aug
;
77
(
2
):
299
305
.
[PubMed]
0169-5002
17.
Yoshida
M
,
Nagatomo
T
,
Ohnishi
T
,
Kawashima
M
,
Naitoh
A
,
Morii
E
.
Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry
.
Mol Clin Oncol
.
2017
Dec
;
7
(
6
):
981
7
.
[PubMed]
2049-9450
18.
Brevet
M
,
Arcila
M
,
Ladanyi
M
.
Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR
.
J Mol Diagn
.
2010
Mar
;
12
(
2
):
169
76
.
[PubMed]
1525-1578
19.
Seo
AN
,
Park
TI
,
Jin
Y
,
Sun
PL
,
Kim
H
,
Chang
H
, et al
Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry
.
Lung Cancer
.
2014
Mar
;
83
(
3
):
316
23
.
[PubMed]
0169-5002
20.
Kawahara
A
,
Yamamoto
C
,
Nakashima
K
,
Azuma
K
,
Hattori
S
,
Kashihara
M
, et al
Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis
.
Clin Cancer Res
.
2010
Jun
;
16
(
12
):
3163
70
.
[PubMed]
1078-0432
21.
Kitamura
A
,
Hosoda
W
,
Sasaki
E
,
Mitsudomi
T
,
Yatabe
Y
.
Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer
.
Clin Cancer Res
.
2010
Jul
;
16
(
13
):
3349
55
.
[PubMed]
1078-0432
22.
Kato
Y
,
Peled
N
,
Wynes
MW
,
Yoshida
K
,
Pardo
M
,
Mascaux
C
, et al
Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations
.
J Thorac Oncol
.
2010
Oct
;
5
(
10
):
1551
8
.
[PubMed]
1556-0864
23.
Kozu
Y
,
Tsuta
K
,
Kohno
T
,
Sekine
I
,
Yoshida
A
,
Watanabe
S
, et al
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma
.
Lung Cancer
.
2011
Jul
;
73
(
1
):
45
50
.
[PubMed]
0169-5002
24.
Nakamura
H
,
Mochizuki
A
,
Shinmyo
T
,
Ando
K
,
Kurimoto
N
,
Yokote
K
, et al
Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma
.
Anticancer Res
.
2010
Dec
;
30
(
12
):
5233
7
.
[PubMed]
1791-7530
25.
Simonetti
S
,
Molina
MA
,
Queralt
C
,
de Aguirre
I
,
Mayo
C
,
Bertran-Alamillo
J
, et al
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
.
J Transl Med
.
2010
Dec
;
8
(
1
):
135
.
[PubMed]
1479-5876
26.
Jiang
G
,
Fan
C
,
Zhang
X
,
Dong
Q
,
Wang
L
,
Liu
Y
, et al
Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer
.
PLoS One
.
2013
;
8
(
3
):
e59183
.
[PubMed]
1932-6203
27.
Kawahara
A
,
Azuma
K
,
Sumi
A
,
Taira
T
,
Nakashima
K
,
Aikawa
E
, et al
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry
.
Lung Cancer
.
2011
Oct
;
74
(
1
):
35
40
.
[PubMed]
0169-5002
28.
Lindeman
NI
,
Cagle
PT
,
Aisner
DL
,
Arcila
ME
,
Beasley
MB
,
Bernicker
EH
, et al
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
.
Arch Pathol Lab Med
.
2018
Mar
;
142
(
3
):
321
46
.
[PubMed]
0003-9985
29.
Pisapia
P
,
Lozano
MD
,
Vigliar
E
,
Bellevicine
C
,
Pepe
F
,
Malapelle
U
, et al
ALK and ROS1 testing on lung cancer cytologic samples: perspectives
.
Cancer Cytopathol
.
2017
Nov
;
125
(
11
):
817
30
.
[PubMed]
1934-662X
30.
Selinger
CI
,
Rogers
TM
,
Russell
PA
,
O’Toole
S
,
Yip
P
,
Wright
GM
, et al
Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization
.
Mod Pathol
.
2013
Dec
;
26
(
12
):
1545
53
.
[PubMed]
0893-3952
31.
Sakairi
Y
,
Nakajima
T
,
Yasufuku
K
,
Ikebe
D
,
Kageyama
H
,
Soda
M
, et al
EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration
.
Clin Cancer Res
.
2010
Oct
;
16
(
20
):
4938
45
.
[PubMed]
1078-0432
32.
Savic
S
,
Bode
B
,
Diebold
J
,
Tosoni
I
,
Barascud
A
,
Baschiera
B
, et al
Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone
.
J Thorac Oncol
.
2013
Aug
;
8
(
8
):
1004
11
.
[PubMed]
1556-0864
33.
Minca
EC
,
Portier
BP
,
Wang
Z
,
Lanigan
C
,
Farver
CF
,
Feng
Y
, et al
ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH
.
J Mol Diagn
.
2013
May
;
15
(
3
):
341
6
.
[PubMed]
1525-1578
34.
Mino-Kenudson
M
,
Chirieac
LR
,
Law
K
,
Hornick
JL
,
Lindeman
N
,
Mark
EJ
, et al
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry
.
Clin Cancer Res
.
2010
Mar
;
16
(
5
):
1561
71
.
[PubMed]
1078-0432
35.
Kim
H
,
Yoo
SB
,
Choe
JY
,
Paik
JH
,
Xu
X
,
Nitta
H
, et al
Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression
.
J Thorac Oncol
.
2011
Aug
;
6
(
8
):
1359
66
.
[PubMed]
1556-0864
36.
Tsao
MS
,
Hirsch
FR
,
Yatabe
Y
, editors
.
IASLC atlas of ALK testing in lung cancer
.
Aurora, Colorado, USA
:
IASLC Press
;
2013
.
37.
Conde
E
,
Suárez-Gauthier
A
,
Benito
A
,
Garrido
P
,
García-Campelo
R
,
Biscuola
M
, et al
Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry
.
PLoS One
.
2014
Sep
;
9
(
9
):
e107200
.
[PubMed]
1932-6203
38.
Gainor
JF
,
Shaw
AT
.
Novel targets in non-small cell lung cancer: ROS1 and RET fusions
.
Oncologist
.
2013
;
18
(
7
):
865
75
.
[PubMed]
1083-7159
39.
Vlajnic
T
,
Savic
S
,
Barascud
A
,
Baschiera
B
,
Bihl
M
,
Grilli
B
, et al
Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry
.
Cancer Cytopathol
.
2018
Jun
;
126
(
6
):
421
9
.
[PubMed]
1934-662X
40.
Selinger
CI
,
Li
BT
,
Pavlakis
N
,
Links
M
,
Gill
AJ
,
Lee
A
, et al
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target
.
Histopathology
.
2017
Feb
;
70
(
3
):
402
11
.
[PubMed]
0309-0167
41.
Yoshida
A
,
Tsuta
K
,
Wakai
S
,
Arai
Y
,
Asamura
H
,
Shibata
T
, et al
Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers
.
Mod Pathol
.
2014
May
;
27
(
5
):
711
20
.
[PubMed]
0893-3952
42.
Takigawa
N
,
Ochi
N
,
Yamane
H
.
Histology versus cytology: PD-L1 testing in non-small cell lung cancer
.
Transl Lung Cancer Res
.
2018
Sep
;
7
(
S3
Suppl 3
):
S225
7
.
[PubMed]
2218-6751
43.
Hirsch
FR
. IASLC Lung Cancer News: PD-L1 IHC Blueprint Project: ongoing progress toward consistency among assays. Last updated 05 April
2018
[Accessed 14 December 2018] http://www.lungcancernews.org/2018/04/05/pd-l1-ihc-blueprint-project-ongoing-progress-toward-consistency-among-assays/
44.
Tsao
MS
,
Kerr
KM
,
Kockx
M
,
Beasley
MB
,
Borczuk
AC
,
Botling
J
, et al
PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 2 Project
.
J Thorac Oncol
.
2018
Sep
;
13
(
9
):
1302
11
.
[PubMed]
1556-0864
45.
Skov
BG
,
Skov
T
.
Paired comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx
.
Appl Immunohistochem Mol Morphol
.
2017
Aug
;
25
(
7
):
453
9
.
[PubMed]
1541-2016
46.
Wang
H
,
Agulnik
J
,
Kasymjanova
G
,
Wang
A
,
Jiménez
P
,
Cohen
V
, et al
Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer
.
Ann Oncol
.
2018
Jun
;
29
(
6
):
1417
22
.
[PubMed]
0923-7534
47.
Noll
B
,
Wang
WL
,
Gong
Y
,
Zhao
J
,
Kalhor
N
,
Prieto
V
, et al
Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations
.
Cancer Cytopathol
.
2018
May
;
126
(
5
):
342
52
.
[PubMed]
1934-662X
48.
Hernandez
A
,
Brandler
TC
,
Zhou
F
,
Moreira
AL
,
Schatz-Siemers
N
,
Simsir
A
.
Assessment of programmed death-ligand 1 (PD-L1) immunohistochemical expression on cytology specimens in non-small cell lung carcinoma: a comparative study with paired surgical specimens
.
Am J Clin Pathol
.
2018
.0002-9173
49.
Thunnissen
E
,
Borczuk
AC
,
Flieder
DB
,
Witte
B
,
Beasley
MB
,
Chung
JH
, et al
The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An international reproducibility study in a demanding set of cases
.
J Thorac Oncol
.
2017
Feb
;
12
(
2
):
334
46
.
[PubMed]
1556-0864
50.
Monaco
SE
,
Dacic
S
. Evaluation of small biopsy material in patients with multiple and secondary tumors. In:
Moreira
AL
,
Saqi
A
, editors
.
Diagnosing non-small cell carcinoma in small biopsy and cytology
.
New York
:
Springer
;
2015
. pp.
155
96
.
51.
Husain
AN
,
Colby
TV
,
Ordóñez
NG
,
Allen
TC
,
Attanoos
RL
,
Beasley
MB
, et al
Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group
.
Arch Pathol Lab Med
.
2018
Jan
;
142
(
1
):
89
108
.
[PubMed]
0003-9985
52.
Hjerpe
A
,
Ascoli
V
,
Bedrossian
C
,
Boon
M
,
Creaney
J
,
Davidson
B
, et al
Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
.
Cytojournal
.
2015
Nov
;
12
(
1
):
26
.
[PubMed]
1742-6413
53.
King
J
,
Thatcher
N
,
Pickering
C
,
Hasleton
P
.
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports
.
Histopathology
.
2006
Dec
;
49
(
6
):
561
8
.
[PubMed]
0309-0167
54.
Illei
PB
,
Rusch
VW
,
Zakowski
MF
,
Ladanyi
M
.
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas
.
Clin Cancer Res
.
2003
Jun
;
9
(
6
):
2108
13
.
[PubMed]
1078-0432
55.
Hwang
HC
,
Sheffield
BS
,
Rodriguez
S
,
Thompson
K
,
Tse
CH
,
Gown
AM
, et al
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens
.
Am J Surg Pathol
.
2016
Jan
;
40
(
1
):
120
6
.
[PubMed]
0147-5185
56.
Andrici
J
,
Sheen
A
,
Sioson
L
,
Wardell
K
,
Clarkson
A
,
Watson
N
, et al
Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
.
Mod Pathol
.
2015
Oct
;
28
(
10
):
1360
8
.
[PubMed]
0893-3952
57.
Carbone
M
,
Yang
H
,
Pass
HI
,
Krausz
T
,
Testa
JR
,
Gaudino
G
.
BAP1 and cancer
.
Nat Rev Cancer
.
2013
Mar
;
13
(
3
):
153
9
.
[PubMed]
1474-175X
58.
Sheffield
BS
,
Hwang
HC
,
Lee
AF
,
Thompson
K
,
Rodriguez
S
,
Tse
CH
, et al
BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations
.
Am J Surg Pathol
.
2015
Jul
;
39
(
7
):
977
82
.
[PubMed]
0147-5185
59.
Churg
A
,
Sheffield
BS
,
Galateau-Salle
F
.
New markers for separating benign from malignant mesothelial proliferations: are we there yet?
Arch Pathol Lab Med
.
2016
Apr
;
140
(
4
):
318
21
.
[PubMed]
0003-9985
60.
Cigognetti
M
,
Lonardi
S
,
Fisogni
S
,
Balzarini
P
,
Pellegrini
V
,
Tironi
A
, et al
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
.
Mod Pathol
.
2015
Aug
;
28
(
8
):
1043
57
.
[PubMed]
0893-3952
61.
Powers
CN
.
Diagnosis of infectious diseases: a cytopathologist’s perspective
.
Clin Microbiol Rev
.
1998
Apr
;
11
(
2
):
341
65
.
[PubMed]
0893-8512
62.
World Health Organization
: Xpert MTB/RIF: WHO policy update and implementation manual. Last updated May
2013
[Accessed 14 December 2018]
63.
Michelow
P
,
Omar
T
,
Field
A
,
Wright
C
.
The cytopathology of mycobacterial infection
.
Diagn Cytopathol
.
2016
Mar
;
44
(
3
):
255
62
.
[PubMed]
8755-1039
64.
Allison
DB
,
Simner
PJ
,
Ali
SZ
.
Identification of infectious organisms in cytopathology: A review of ancillary diagnostic techniques
.
Cancer Cytopathol
.
2018
Aug
;
126
Suppl 8
:
643
53
.
[PubMed]
1934-662X
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.